GSK PLC Sponsored ADR $GSK Stake Lifted by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD lifted its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 1.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,965,946 shares of the pharmaceutical company’s stock after buying an additional 55,116 shares during the period. GSK makes up 5.2% of Mondrian Investment Partners LTD’s investment portfolio, making the stock its 4th largest holding. Mondrian Investment Partners LTD’s holdings in GSK were worth $239,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the stock. NewEdge Advisors LLC raised its stake in GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after acquiring an additional 852,437 shares in the last quarter. Waverly Advisors LLC lifted its position in GSK by 1,372.8% in the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after acquiring an additional 270,863 shares during the last quarter. Keystone Financial Planning Inc. lifted its position in GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock valued at $10,253,000 after acquiring an additional 189,506 shares during the last quarter. Kahn Brothers Group Inc. purchased a new stake in GSK in the second quarter valued at $8,305,000. Finally, Dorsey Wright & Associates acquired a new position in GSK in the first quarter valued at $2,522,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK opened at $50.74 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The firm has a market cap of $102.64 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. The company’s 50 day simple moving average is $49.59 and its 200-day simple moving average is $51.45. GSK PLC Sponsored ADR has a 12-month low of $42.85 and a 12-month high of $61.69.

GSK (NYSE:GSK) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same period in the previous year, the company posted $0.47 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were given a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date of this dividend was Friday, August 14th. This is an increase from GSK’s previous quarterly dividend of $0.44. GSK’s payout ratio is 55.31%.

Analyst Ratings Changes

Several equities analysts have issued reports on GSK shares. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of GSK in a report on Tuesday, September 29th. The Goldman Sachs Group reiterated a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Morgan Stanley reissued an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Citigroup initiated coverage on GSK in a research report on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $55.33.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.